No products in the cart.
Retatrutide for Weight Loss: Benefits, Dosage & Where to Buy Wholesale
? Retatrutide Overview
Retatrutide (Eli Lilly’s triple-hormone agonist) is the next-generation obesity and type 2 diabetes treatment, outperforming Wegovy® and Mounjaro® in clinical trials with 24.2% average weight loss at 48 weeks. As a trusted supplier, we offer factory-direct Retatrutide injections at competitive wholesale prices for clinics, pharmacies, and distributors.
? Key Features
- Triple-action formula (GLP-1 + GIP + Glucagon receptors)
- 24%+ weight loss demonstrated in Phase 2 trials
- Weekly subcutaneous injection (2.5mg–12mg doses)
- FDA Fast Track designation (expected approval: 2025-2026)
- MOQ 100 kits | GMP-certified production | Door-to-door shipping
? Retatrutide vs. Alternatives
| Drug | Mechanism | Avg. Weight Loss | Price (Wholesale)** |
|---|---|---|---|
| Retatrutide | GLP-1/GIP/GCG | 24.2% (48 wks) | $XXX/kits (Contact for quote) |
| Mounjaro® | GLP-1/GIP | 25% (52 wks) | $XXX |
| Wegovy® | GLP-1 only | 15% (68 wks) | $XXX |
? Pro Tip: Retatrutide achieves comparable results to Mounjaro in 4 fewer weeks – a key advantage for weight-loss clinics.
? Retatrutide Specifications
? Product Details
- Active Ingredient: Retatrutide (LY3437943)
- Form: Pre-filled pen injector
- Dosage: 2.5mg, 5mg, 10mg, 12mg
- Packaging: 4 pens/box (Tray of 10 boxes)
- Shelf Life: 24 months (Store at 2-8°C)
? Shipping & Logistics
- Global delivery (DHL/FedEx Cold Chain)
- Express 3-5 days (Europe/North America)
- Customs clearance support
? Retatrutide Clinical Applications
1. Obesity Management
Retatrutide’s triple-hormone action suppresses appetite AND increases fat burning – unlike single-action drugs like Semaglutide. Clinical results show:
- 17.5% weight loss in 24 weeks
- 24.2% loss by 48 weeks (NEJM 2023 study)
2. Type 2 Diabetes Control
- HbA1c reduction: 1.8–2.4%
- Weight loss synergy: Ideal for diabetics struggling with obesity
3. NAFLD/NASH Treatment
Early data suggests 27% liver fat reduction – a breakthrough for metabolic liver disease.
?? Side Effects & Safety
Most side effects are mild and transient:
- Common (10-30%): Nausea, diarrhea, mild abdominal pain
- Rare (<5%): Vomiting, constipation
- No severe hypoglycemia reported in trials
? For Clinicians: Start patients at 2.5mg/week, titrating up every 4 weeks to minimize GI effects.
? Frequently Asked Questions
Q: Is Retatrutide available for wholesale purchase?
A: Yes! We supply GMP-certified Retatrutide to licensed buyers. Minimum order: 100 kits. [Contact us] for bulk pricing.
Q: How does Retatrutide compare to Ozempic®?
A: Retatrutide targets 3 hormone pathways vs. Ozempic’s 1 (GLP-1 only), delivering 2X faster weight loss in trials.
Q: What’s the best storage protocol?
A: Refrigerate at 2-8°C (do not freeze). Stable for 28 days at room temperature after first use.
Q: When will Retatrutide launch commercially?
A: Expected 2025-2026 (Phase 3 trials complete Q4 2024). Pre-orders now open for qualified buyers.
? Why Choose Our Retatrutide Supply?
- ? Factory pricing: 30-50% below branded alternatives
- ? Third-party lab tested (COA available)
- ?? Discreet shipping with temperature monitoring
- ? Dedicated B2B support for clinics/pharmacies
?? Key Takeaways for Buyers
- Retatrutide is the most advanced obesity drug in development, with superior efficacy to Wegovy/Mounjaro.
- Pre-launch wholesale orders ensure early market access.
- Cold-chain logistics guarantee product stability.
? Contact our sales team today for bulk quotes and clinical trial supply options!
